Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies

por El-Mallawany, N K, Frazer, J K, Van Vlierberghe, P, Ferrando, A A, Perkins, S, Lim, M, Chu, Y, Cairo, M S
Publicado 2012

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

por Degryse, S, de Bock, C E, Demeyer, S, Govaerts, I, Bornschein, S, Verbeke, D, Jacobs, K, Binos, S, Skerrett-Byrne, D A, Murray, H C, Verrills, N M, Van Vlierberghe, P, Cools, J, Dun, M D
Publicado 2018

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

por Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., Verrills, N. M., Van Vlierberghe, P., Cools, J., Dun, M. D.
Publicado 2018

PRL3 enhances T cell acute lymphoblastic leukemia growth through suppressing T cell signaling pathways and apoptosis

por Garcia, E.G., Veloso, A., Oliveira, M.L., Allen, J. R., Loontiens, S., Brunson, D., Do, D., Yan, C., Morris, R., Iyer, S., Garcia, S.P., Iftimia, N., a, Loocke W., Matthijssens, F., McCarthy, K., Barata, J.T., Speleman, F., Taghon, T., Gutierrez, A., Van Vlierberghe, P., Haas, W., Blackburn, J.S., Langenau, D.M.
Publicado 2020